{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:43:17Z","timestamp":1740148997910,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12325-019-01210-2","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T06:02:42Z","timestamp":1579154562000},"page":"906-917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and Efficacy of Combined Oral Contraceptive Ethinyl Estradiol\/Drospirenone (YAZ) in Chinese Women: A Single-Arm, Open-Label, Multicenter, Post-Authorization Study"],"prefix":"10.1007","volume":"37","author":[{"given":"Xin","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangbo","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaojuan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Di","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,16]]},"reference":[{"key":"1210_CR1","unstructured":"United Nations. World Contraceptive Patterns 2013. Department of Economic and Social Affairs, Population Division [Internet]. http:\/\/www.un.org\/en\/development\/desa\/population\/publications\/pdf\/family\/worldContraceptivePatternsWallChart2013.pdf."},{"key":"1210_CR2","first-page":"U683","volume":"116","author":"FA Goodyear-Smith","year":"2003","unstructured":"Goodyear-Smith FA, Arroll B. Contraception before and after termination of pregnancy: can we do it better? N Z Med J. 2003;116:U683.","journal-title":"N Z Med J"},{"key":"1210_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/1054773810375982","volume":"19","author":"L Wu","year":"2010","unstructured":"Wu L. A survey on the knowledge, attitude, and behavior regarding contraception use among pregnant teenagers in Beijing, China. Clin Nurs Res. 2010;19:403\u201315.","journal-title":"Clin Nurs Res."},{"key":"1210_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0002-9378(98)70047-X","volume":"179","author":"MJ Rosenberg","year":"1998","unstructured":"Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577\u201382.","journal-title":"Am J Obstet Gynecol"},{"key":"1210_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.contraception.2011.02.013","volume":"84","author":"J Bitzer","year":"2011","unstructured":"Bitzer J, Simon JA. Current issues and available options in combined hormonal contraception. Contraception. 2011;84:342\u201356.","journal-title":"Contraception"},{"key":"1210_CR6","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1067\/mob.2002.122988","volume":"186","author":"PJ Sulak","year":"2002","unstructured":"Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day\/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"1210_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.contraception.2006.02.006","volume":"74","author":"SA Willis","year":"2006","unstructured":"Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary\u2013ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006;74:100\u20133.","journal-title":"Contraception."},{"key":"1210_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0015-0282(99)00205-8","volume":"72","author":"H Sullivan","year":"1999","unstructured":"Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril. 1999;72:115\u201320.","journal-title":"Fertil Steril"},{"key":"1210_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","volume":"70","author":"G Bachmann","year":"2004","unstructured":"Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3\u00a0mg drospirenone. Contraception. 2004;70:191\u20138.","journal-title":"Contraception."},{"key":"1210_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.contraception.2007.11.003","volume":"77","author":"W Koltun","year":"2008","unstructured":"Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, et al. Efficacy and safety of 3\u00a0mg drospirenone\/20 mcg ethinylestradiol oral contraceptive administered in 24\/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008;77:249\u201356.","journal-title":"Contraception."},{"key":"1210_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/01.AOG.0000175834.77215.2e","volume":"106","author":"KA Yonkers","year":"2005","unstructured":"Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492\u2013501.","journal-title":"Obstet Gynecol"},{"key":"1210_CR12","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2165\/00003495-200767120-00007","volume":"67","author":"C Fenton","year":"2007","unstructured":"Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone\/ethinylestradiol 3\u00a0mg\/20microg (24\/4\u00a0day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs. 2007;67:1749\u201365.","journal-title":"Drugs."},{"key":"1210_CR13","first-page":"721","volume":"53","author":"DR Mishell","year":"2008","unstructured":"Mishell DR. YAZ and the novel progestin drospirenone. J Reprod Med. 2008;53:721\u20138.","journal-title":"J Reprod Med"},{"key":"1210_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.contraception.2010.10.010","volume":"84","author":"J Marr","year":"2011","unstructured":"Marr J, Niknian M, Shulman LP, Lynen R. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3\u00a0mg administered in a 24\/4 regimen. Contraception. 2011;84:81\u20136.","journal-title":"Contraception."},{"key":"1210_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.contraception.2004.07.010","volume":"71","author":"M Sangthawan","year":"2005","unstructured":"Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3\u00a0mg or levonorgestrel 150\u00a0\u03bcg on premenstrual symptoms. Contraception. 2005;71:1\u20137.","journal-title":"Contraception."},{"key":"1210_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.contraception.2008.02.019","volume":"78","author":"C Klipping","year":"2008","unstructured":"Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24\/4 regimen. Contraception. 2008;78:16\u201325.","journal-title":"Contraception."},{"key":"1210_CR17","first-page":"261","volume":"95","author":"PJ Sulak","year":"2000","unstructured":"Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261\u20136.","journal-title":"Obstet Gynecol"},{"key":"1210_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.contraception.2009.01.016","volume":"80","author":"L Hern\u00e1di","year":"2009","unstructured":"Hern\u00e1di L, Marr J, Trummer D, De Leo V, Petraglia F. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3\u00a0mg and ethinylestradiol 20 mcg in a 24\/4-day regimen. Contraception. 2009;80:18\u201324.","journal-title":"Contraception."},{"key":"1210_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/13625180008500387","volume":"5","author":"JM Foidart","year":"2000","unstructured":"Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5:124\u201334.","journal-title":"Eur J Contracept Reprod Health Care."},{"key":"1210_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13625180008500375","volume":"5","author":"J Huber","year":"2000","unstructured":"Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000;5:25\u201334.","journal-title":"Eur J Contracept Reprod Health Care."},{"key":"1210_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0010-7824(00)00083-4","volume":"61","author":"KS Parsey","year":"2000","unstructured":"Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61:105\u201311.","journal-title":"Contraception."},{"key":"1210_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejogrb.2010.12.037","volume":"155","author":"L Anttila","year":"2011","unstructured":"Anttila L, Bachmann G, Hern\u00e1di L, Kunz M, Marr J, Klipping C. Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20\u00a0\u03bcg\/drospirenone 3\u00a0mg administered in a 24\/4 regimen: a pooled analysis of four open-label studies. Eur J Obstet Gynecol Reprod Biol. 2011;155:180\u20132.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1210_CR23","first-page":"355","volume":"49","author":"C Wang","year":"2014","unstructured":"Wang C, Di W, Liao Q, Shen H, Han Z, Tang L, et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20ug in a 24 + 4-day regimen in China. Chin J Obstet Gynecol. 2014;49:355\u20139.","journal-title":"Chin J Obstet Gynecol."},{"key":"1210_CR24","unstructured":"COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) [Internet]. 2005. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-clinical-investigation-steroid-contraceptives-women_en.pdf."},{"key":"1210_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejogrb.2012.01.021","volume":"162","author":"J Marr","year":"2012","unstructured":"Marr J, Gerlinger C, Kunz M. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30\u00a0\u03bcg\/drospirenone 3\u00a0mg administered in a 21\/7 regimen versus ethinylestradiol 20\u00a0\u03bcg\/drospirenone 3\u00a0mg administered in a 24\/4 regimen. Eur J Obstet Gynecol Reprod Biol. 2012;162:91\u20135.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1210_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jfprhc-2011-100213","volume":"38","author":"C Klipping","year":"2012","unstructured":"Klipping C, Duijkers I, Fortier MP, Marr J, Trummer D, Elliesen J. Contraceptive efficacy and tolerability of ethinylestradiol 20\u00a0\u00b5g\/drospirenone 3\u00a0mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study. J Fam Plan Reprod Health Care. 2012;38:73\u201383.","journal-title":"J Fam Plan Reprod Health Care."},{"key":"1210_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.contraception.2009.10.010","volume":"81","author":"RB Machado","year":"2010","unstructured":"Machado RB, de Melo NR, Maia H. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. Contraception. 2010;81:215\u201322.","journal-title":"Contraception."},{"key":"1210_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/BF03256908","volume":"1","author":"F Guang-Sheng","year":"2010","unstructured":"Guang-Sheng F, Mei-Lu B, Li-Nan C, Xiao-Ming C, Zi-Rong H, Zi-Yan H, et al. Efficacy and Safety of the Combined Oral Contraceptive Ethinylestradiol\/Drospirenone (Yasmin\u00ae) in Healthy Chinese Women: A Randomized, Open-Label, Controlled. Multicentre Trial. Clinical Drug Investigation. 2010;1:387\u201396.","journal-title":"Multicentre Trial. Clinical Drug Investigation."},{"key":"1210_CR29","doi-asserted-by":"crossref","unstructured":"Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester: John Wiley & Sons, Ltd; 2012 [cited 2018 Dec 4]. http:\/\/doi.wiley.com\/10.1002\/14651858.CD004425.pub6.","DOI":"10.1002\/14651858.CD004425.pub6"},{"key":"1210_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3109\/13625187.2011.614363","volume":"16","author":"UM \u00c5gren","year":"2011","unstructured":"\u00c5gren UM, Anttila M, M\u00e4enp\u00e4\u00e4-Liukko K, Rantala M-L, Rautiainen H, Sommer WF, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17\u03b2-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function. Eur J Contracept Reprod Health Care. 2011;16:458\u201367.","journal-title":"Eur J Contracept Reprod Health Care."},{"key":"1210_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/humupd\/dmt038","volume":"20","author":"Y Zimmerman","year":"2014","unstructured":"Zimmerman Y, Eijkemans MJC, Coelingh Bennink HJT, Blankenstein MA, Fauser BCJM. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:76\u2013105.","journal-title":"Hum Reprod Update."},{"key":"1210_CR32","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/AOG.0b013e318187e1c5","volume":"112","author":"JM Maloney","year":"2008","unstructured":"Maloney JM, Dietze P, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, et al. Treatment of acne using a 3-milligram drospirenone\/20-microgram ethinyl estradiol oral contraceptive administered in a 24\/4 regimen: a randomized controlled trial. Obstet Gynecol. 2008;112:773\u201381.","journal-title":"Obstet Gynecol"},{"key":"1210_CR33","first-page":"85","volume":"48","author":"G Zhang","year":"2015","unstructured":"Zhang G, Lin T, Sun Q. An oral contraceptive containing ethinyl estradiol and drospirenone for the treatment of women with moderate acne vulgaris: a randomized, multicenter, placebo-controlled clinical trial. Chin J Dermatol. 2015;48:85\u20139.","journal-title":"Chin J Dermatol."},{"key":"1210_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5468\/ogs.2015.58.5.397","volume":"58","author":"N Kim","year":"2015","unstructured":"Kim N, Yoo H-N, Hyun HS, Lee D-Y, Yoon B-K, Choi D-S. Efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive in Korean women. Obstet Gynecol Sci. 2015;58:397\u2013400.","journal-title":"Obstet Gynecol Sci."},{"key":"1210_CR35","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/bmj.332.7550.1134","volume":"332","author":"M Proctor","year":"2006","unstructured":"Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. BMJ. 2006;332:1134\u20138.","journal-title":"BMJ"},{"key":"1210_CR36","first-page":"2011","volume":"21","author":"PM Latthe","year":"2011","unstructured":"Latthe PM, Champaneria R, Khan KS. Dysmenorrhoea. BMJ Clin Evid. 2011;21:2011.","journal-title":"BMJ Clin Evid."},{"key":"1210_CR37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/IJWH.S134576","volume":"9","author":"M Momoeda","year":"2017","unstructured":"Momoeda M, Kondo M, Elliesen J, Yasuda M, Yamamoto S, Harada T. Efficacy and safety of a flexible extended regimen of ethinylestradiol\/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study. Int J Womens Health. 2017;9:295\u2013305.","journal-title":"Int J Womens Health."},{"key":"1210_CR38","first-page":"989","volume":"6","author":"M Momoeda","year":"2014","unstructured":"Momoeda M, Hayakawa M, Shimazaki Y, Mizunuma H, Taketani Y. Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen\/progestin, ethinylestradiol\/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. Int J Womens Health. 2014;6:989\u201398.","journal-title":"Int J Womens Health."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01210-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01210-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01210-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T16:01:05Z","timestamp":1665504065000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01210-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01210-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2020,1,16]]},"assertion":[{"value":"16 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}